A Phase 3 interventional study of TAK-019 in Coronavirus Disease (COVID-19), sponsored by Takeda. Completed at 2 sites in Japan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-21.
Sponsored by Takeda · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 — none open to participants now, 2 under way, none of them phase 3. NVX-CoV2373 adjuvated lipid nanoparticle · COVID-19.
Among the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19, this one is the 16th largest by enrollment, is one of 5 that started in 2022, is one of 7 in phase 3, and was the 7th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →None of the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 is open now. The open studies under COVID-19, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 20 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 9 · Phase 4 5
First in 2020; this study’s year is marked. 5 started in 2022.
This study's enrollment of 150 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 997 across the 18 interventional studies. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 18 have an industry lead sponsor. The 7 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Takeda has 4 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
1 of the studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07861542SanofiStudy of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19 | 2026-11-26 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19, from their registry updates:
This tab as a report to print or save as PDF → With an account.
TAK-019 is a vaccine in development to protect people against Covid-19. The main aims of the study are to learn if TAK-019 can protect people from Covid-19 and to check for side effects from TAK-019 for participants who will receive TAK-019 as heterologous booster vaccination.
This study consists of two parts, main part and extension part. Firstly, participants who completed 2 doses primary vaccinations 6 to 12 months prior to the trial vaccination can take part in main study. At the first visit of main part of this study, the study doctor will check if each person can take part. Participants who can take part will receive an injection of TAK-019 as booster vaccination.
Participants will be asked to record their temperature and any medical problems in an electronic diary for up to 7 days after the injection. During the main part, participants will visit the clinic for regular check-ups, blood tests, and sometimes for nose swab samples. When all participants have attended a clinic visit 28 days after the injection, the study sponsor (Takeda) will check how many participants have made enough antibodies to protect them against Covid-19.
Participants who received the first single booster vaccination of TAK-019 in the main part and remained in study follow-up at least 5 months will be able to decide to take part in the extension part of this study. At the first visit of extension part of this study, the study doctor will check if each person can take part. Participants who can take part will receive an injection of TAK-019 as a second booster vaccination at the first visit of extension part.
The participants will stay in the main part of this study for up to 12 months after they have had their injection or up to the start of extension part. For participants who will take part in the extension part, they will stay in the extension part for up to 12 months from the start of extension part. During this time, the doctors will continue to collect blood samples to check immune response. Also, they will check if participants have any more side effects from TAK-019.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
MAIN PART:
Participant who completed 2 doses primary vaccinations with another specified mRNA vaccine which is available in Japan 6 to 12 months prior to the trial vaccination.
EXTENSION PART:
Exclusion Criteria:
MAIN PART:
Participants with (BMI) greater than or equal to 30 kg/m\^2 (BMI= weight in kg/ height in meters\^2)
EXTENSION PART:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-019 0.5 mL, intramuscular injection in the mid deltoid, preferable in the non-dominant upper arm
Biological: TAK-019
TAK-019 0 .5 mL, intramuscular injection in the mid deltoid, preferable in the non-dominant upper arm. The participants who received the first single booster vaccination of TAK-019 in the main part and remained in study follow-up at least 5 months will receive a second single booster vaccination of TAK-019 by intramuscular injection.
Biological: TAK-019
TAK-019 intramuscular injection
Main Part: Geometric Mean Titers (GMT) Ratio of Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Day 15 Compared With That Observed on Day 36 in Participants From the TAK-019-1501 Study
GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values was measured as below lower limit of quantification (LLOQ) were imputed to a value that was half of the LLOQ. LLOQ was equal to 20. GMT for each group and GMT ratio of neutralizing antibody titers to the ancestral strain (wild-type virus) on Day15 after a single booster vaccination (14 days after the booster vaccination) compared with that observed on Day 36 (14 days after the second vaccination) in participants from the TAK-019-1501 study (NCT04712110) were reported. GMT ratio was calculated with GMT of TAK-019-3001 on Day 15 divided by GMT of TAK-019-1501 study on Day 36. Here, ELISA is Enzyme-linked immunosorbent assay.
Time frame: Day 15 for this study (14 days after the vaccination); Day 36 for TAK-019-1501 study (14 days after the second vaccination)
Main Part: Percentage of Participants With Reported Solicited Local Adverse Events (AEs) for 7 Days Following the First Single Booster Vaccination
AE was defined as any untoward medical occurrence in a clinical investigation participant administered an investigational medicinal product (IMP); it did not necessarily have to have a causal relationship with IMP administration. Reported solicited local AEs were defined as injection site pain, tenderness, erythema/redness, induration, and swelling.
Time frame: Main Part: 7 days after the first single booster vaccination
Main Part: Percentage of Participants With Solicited Systemic AEs for 7 Days Following the First Single Booster Vaccination
Solicited systemic AEs were defined as fever, fatigue, malaise, myalgia, arthralgia, nausea/vomiting, and headache.
Time frame: Main Part: 7 days after the first single booster vaccination
Main Part: Percentage of Participants With Unsolicited AEs for 28 Days Following the First Single Booster Vaccination
Unsolicited AEs defines as other AEs than solicited local AEs and solicited systemic AEs.
Time frame: Main Part: 28 days after the first single booster vaccination
Main Part: Percentage of Participants With Solicited and Unsolicited Serious Adverse Events (SAE) Until Day 29
An SAE was defined as any untoward medical occurrence that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event. Solicited SAEs and unsolicited SAEs were reported.
Time frame: Main Part: Up to Day 29
Main Part: Percentage of Participants With Adverse Event of Special Interest (AESI) Until Day 29
An AESI was defined as AEs that will be specifically highlighted to the Investigator. AESIs for the study included the Potential Immune Mediated Medical Conditions (PIMMC) and AEs specific to COVID-19. PIMMC is categorized as following; neuroinflammatory disorders, musculoskeletal and connective tissue disorders, vasculitides, gastrointestinal disorders, hepatic disorders, renal disorders, cardiac disorders, skin disorder, hematologic disorders, metabolic disorders, and other disorders.
Time frame: Main Part: Up to Day 29
Main Part: Percentage of Participants With Medically-Attended Adverse Events (MAAEs) Until Day 29
MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.
Time frame: Main Part: Up to Day 29
Main Part: Percentage of Participants With Any AE Leading to Withdrawal From the Trial Until Day 29
Percentage of participants with any AE leading to withdrawal from the trial until Day 29 was reported.
Time frame: Main Part: Up to Day 29
Main Part: Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Until Day 29
Percentage of participants with SARS-CoV-2 infection until Day 29 of the main part of the trial were reported in this outcome measure.
Time frame: Main Part: Up to Day 29
Main Part: GMT of Serum Immunoglobulin G (IgG) Antibody Levels to SARS-CoV-2 Recombinant Spike (rS) Protein on Day 8, 15, 29, 91, 181, and 366
GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ. LLOQ was equal to 200 EU/mL.
Time frame: Main Part: Day 8, 15, 29, 91, 181, and 366
Main Part: Geometric Mean Fold Rise (GMFR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 8, 15, 29, 91, 181, and 366
GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Where baseline was defined as the last measurement taken before the first dose of trial vaccination.
Time frame: Main Part: Day 8, 15, 29, 91, 181, and 366
Main Part: Seroconversion Rate (SCR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 8, 15, 29, 91, 181, and 366
SCR was defined as percentage of participants with 4-fold or more rises from baseline in titer. Baseline was defined as the last measurement taken before the first dose of trial vaccination.
Time frame: Main Part: Day 8, 15, 29, 91, 181, and 366
Main Part: GMT of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Day 8, 15, 29, 91, 181, and 366
The neutralization titer was expressed as the reciprocal of the highest dilution at which greater than or equal to (\>=) 50 percent (%) of the replicate wells were protected from infection (microneutralization \[MN\] with an inhibitory concentration of 50% \[MN50\]). GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ where LLOQ was equal to 20.
Time frame: Main Part: Day 8, 15, 29, 91, 181, and 366
Main Part: GMFR of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Day 8, 15, 29, 91, 181, and 366
The neutralization titer was expressed as the reciprocal of the highest dilution at which \>=50% of the replicate wells were protected from infection (MN50). GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Baseline was defined as the last measurement taken before the first dose of trial vaccination.
Time frame: Main Part: Day 8, 15, 29, 91, 181, and 366
Main Part: SCR of Serum Neutralizing Antibody Titters to the Ancestral Strain (Wild-type Virus) on Day 8, 15, 29, 91, 181, and 366
The neutralization titer was expressed as the reciprocal of the highest dilution at which greater than or equal to (\>=) 50% of the replicate wells were protected from infection (MN50). SCR was defined as percentage of participants with 4-fold or more rises in from baseline. Baseline was defined as the last measurement taken before the first dose of trial vaccination.
Time frame: Main Part: Day 8, 15, 29, 91, 181, and 366
Main Part: Percentage of Participants With Solicited and Unsolicited SAEs Throughout the Main Part of Trial
An SAE was defined as any untoward medical occurrence that: Results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event. Solicited SAEs and unsolicited SAEs were reported.
Time frame: Main Part: Up to Day 366
Main Part: Percentage of Participants With AESI Throughout the Main Part of Trial
An AESI was defined as AEs that will be specifically highlighted to the Investigator. AESIs for the study included the PIMMC and AEs specific to COVID-19. PIMMC is categorized as following; neuroinflammatory disorders, musculoskeletal and connective tissue disorders, vasculitides, gastrointestinal disorders, hepatic disorders, renal disorders, cardiac disorders, skin disorder, hematologic disorders, metabolic disorders, and other disorders.
Time frame: Main Part: Up to Day 366
Main Part: Percentage of Participants With MAAEs Throughout the Main Part of Trial
MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.
Time frame: Main Part: Up to Day 366
Main Part: Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial From the Day of the First Single Booster Vaccination Throughout the Main Part of Trial
Percentage of participants with any AE leading to participant's withdrawal from the trial from the day of the first single booster vaccination throughout the main part of trial was reported.
Time frame: Main Part: Day 1 up to Day 366
Main Part: Percentage of Participants With SARS-CoV-2 Infection Throughout the Main Part of Trial
Percentage of participants with SARS-CoV-2 infection throughout the main part of trial was reported.
Time frame: Main Part: Day 1 up to Day 366
Extension Part: GMT of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 15, 29, 91, 181, and 366
GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ. LLOQ was equal to 200 EU/mL.
Time frame: Extension Part: Day 15, 29, 91, 181, and 366
Extension Part: GMFR of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Extension Part Day 15, 29, 91, 181, and 366
The GMFR was calculated as the ratio of the post-second-booster-vaccination titer level to extension part baseline titer level. Where extension part baseline was defined as last measurement taken before the second booster vaccination.
Time frame: Extension Part: Day 15, 29, 91, 181, and 366
Extension Part: Seroconversion Rate (SCR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Extension Part Day 15, 29, 91, 181, and 366
SCR was defined as percentage of participants with 4-fold or more rises in titer from extension part baseline. Where extension part baseline was defined as last measurement taken before the second booster vaccination.
Time frame: Extension Part: Day 15, 29, 91, 181, and 366
Extension Part: GMT of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Extension Part Day 15, 29, 91, 181, and 366
The neutralization titer was expressed as the reciprocal of the highest dilution at \>= 50% of the replicate wells were protected from infection (MN50). GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ where LLOQ was equal to 20.
Time frame: Extension Part: Day 15, 29, 91, 181, and 366
Extension Part: GMFR of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Extension Part Day 15, 29, 91, 181, and 366
The neutralization titer was expressed as the reciprocal of the highest dilution at \>= 50% of the replicate wells were protected from infection (MN50). The GMFR was calculated as the ratio of the post-second-booster-vaccination titer level to extension part baseline titer level. Where extension part baseline was defined as last measurement taken before the second booster vaccination.
Time frame: Extension Part: Day 15, 29, 91, 181, and 366
Extension Part: SCR of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Extension Part Day 15, 29, 91, 181, and 366
The neutralization titer was expressed as the reciprocal of the highest dilution at \>= 50% of the replicate wells were protected from infection (MN50). SCR was defined as percentage of participants with 4-fold or more rises in titer from extension part baseline.
Time frame: Extension Part: Day 15, 29, 91, 181, and 366
Extension Part: Percentage of Participants With Reported Solicited Local AEs for 7 Days Following the Second Single Booster Vaccination in Extension Part
AE was defined as any untoward medical occurrence in a clinical investigation participant administered an investigational medicinal product (IMP); it did not necessarily have to have a causal relationship with IMP administration. Reported solicited local AEs were defined as injection site pain, tenderness, erythema/redness, induration, and swelling.
Time frame: Extension Part: 7 days after the second single booster vaccination
Extension Part: Percentage of Participants With Solicited Systemic AEs for 7 Days Following the Second Single Booster Vaccination in Extension Part
Solicited systemic AEs included were defined as fever, fatigue, malaise, myalgia, arthralgia, nausea/vomiting and headache.
Time frame: Extension Part: 7 days after the second single booster vaccination
Extension Part: Percentage of Participants With Unsolicited AEs for 28 Days Following the Second Single Booster Vaccination in Extension Part
Unsolicited AEs defined as AEs other than solicited local AEs and solicited systemic AEs.
Time frame: Extension Part: 28 days after the second single booster vaccination
Extension Part: Percentage of Participants With Solicited and Unsolicited SAEs Until Extension Part Day 29
An SAE was defined as any untoward medical occurrence that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event. Solicited SAEs and unsolicited SAEs were reported.
Time frame: Extension Part: Up to Day 29
Extension Part: Percentage of Participants With AESIs Until Extension Part Day 29
An AESI was defined as AEs that will be specifically highlighted to the investigator. AESIs for the study included the PIMMC and AEs specific to COVID-19. PIMMC is categorized as following; neuroinflammatory disorders, musculoskeletal and connective tissue disorders, vasculitides, gastrointestinal disorders, hepatic disorders, renal disorders, cardiac disorders, skin disorder, hematologic disorders, metabolic disorders, and other disorders.
Time frame: Extension Part: Up to Day 29
Extension Part: Percentage of Participants With MAAEs Until Extension Part Day 29
MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.
Time frame: Extension Part: Up to Day 29
Extension Part: Percentage of Participants With Any AEs Leading to Withdrawal From the Trial Until Extension Part Day 29
Percentage of participants with any AEs leading to withdrawal from the trial until extension part Day 29 was reported.
Time frame: Extension Part: Up to Day 29
Extension Part: Percentage of Participants With SARS-CoV-2 Infection Until Extension Part Day 29
Percentage of participants with SARS-CoV-2 infection until extension part Day 29 was reported.
Time frame: Extension Part: Up to Day 29
Extension Part: Percentage of Participants With Solicited and Unsolicited SAEs Throughout the Extension Part of the Trial
An SAE was defined as any untoward medical occurrence that: Results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Leads to a congenital anomaly/birth defect in the offspring of a participant, or Is an important medical event. Solicited SAEs and unsolicited SAEs were reported.
Time frame: Extension Part: Up to Day 366
Extension Part: Percentage of Participants With AESIs Throughout the Extension Part of the Trial
An AESI was defined as AEs that will be specifically highlighted to the Investigator. AESIs for the study included the PIMMC and AEs specific to COVID-19. PIMMC is categorized as following; neuroinflammatory disorders, musculoskeletal and connective tissue disorders, vasculitides, gastrointestinal disorders, hepatic disorders, renal disorders, cardiac disorders, skin disorder, hematologic disorders, metabolic disorders, and other disorders.
Time frame: Extension Part: Up to Day 366
Extension Part: Percentage of Participants With MAAEs Throughout the Extension Part of the Trial
MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.
Time frame: Extension Part: Up to Day 366
Extension Part: Percentage of Participants With Any AEs Leading to Withdrawal From the Trial From the Day of the Second Single Booster Vaccination Throughout the Extension Part of the Trial
Percentage of participants with any AEs leading to withdrawal from the trial from the day of the second single booster vaccination throughout the extension part of the trial was reported.
Time frame: Extension Part: From Day 1 up to Day 366
Extension Part: Percentage of Participants With SARS-CoV-2 Infection Throughout the Extension Part of Trial
Percentage of participants with SARS-CoV-2 infection throughout the extension part of trial was reported.
Time frame: Extension Part: Up to Day 366
Participants took part in the study at 2 investigative sites in Japan. Healthy Japanese participants who completed 2 doses of primary vaccinations 6 to 12 months prior to trial vaccination were enrolled to receive a first dose of single booster vaccination of TAK-019 in Main Part and a second dose of booster vaccination of TAK-019 in Extension Part.
| Milestone | Main Part: TAK-019 | Extension Part: TAK-019 |
|---|---|---|
| Started | 150 | 0 |
| Completed | 17 | 0 |
| Not completed | 133 | 0 |
| Withdrew: Participants moved to extension part | 129 | 0 |
| Withdrew: Other | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Milestone | Main Part: TAK-019 | Extension Part: TAK-019 |
|---|---|---|
| Started | 0 | 129 |
| Completed | 0 | 121 |
| Not completed | 0 | 8 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 5 |
| Withdrew: Other | 0 | 1 |
GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values was measured as below lower limit of quantification (LLOQ) were imputed to a value that was half of the LLOQ. LLOQ was equal to 20. GMT for each group and GMT ratio of neutralizing antibody titers to the ancestral strain (wild-type virus) on Day15 after a single booster vaccination (14 days after the booster vaccination) compared with that observed on Day 36 (14 days after the second vaccination) in participants from the TAK-019-1501 study (NCT04712110) were reported. GMT ratio was calculated with GMT of TAK-019-3001 on Day 15 divided by GMT of TAK-019-1501 study on Day 36. Here, ELISA is Enzyme-linked immunosorbent assay.
| ELISA units per mL (EU/mL) | Main Part: Day 15 of This Study: TAK-019 | Day 36 for TAK-019-1501 Study |
|---|---|---|
| Main Part: Geometric Mean Titers (GMT) Ratio of Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Day 15 Compared With That Observed on Day 36 in Participants From the TAK-019-1501 Study | 1143.9 (1000.5 to 1307.9) | 884.4 (749.0 to 1044.4) |
AE was defined as any untoward medical occurrence in a clinical investigation participant administered an investigational medicinal product (IMP); it did not necessarily have to have a causal relationship with IMP administration. Reported solicited local AEs were defined as injection site pain, tenderness, erythema/redness, induration, and swelling.
| Percentage of Participants | Main Part: TAK-019 |
|---|---|
| Main Part: Percentage of Participants With Reported Solicited Local Adverse Events (AEs) for 7 Days Following the First Single Booster Vaccination | 74.0 |
Solicited systemic AEs were defined as fever, fatigue, malaise, myalgia, arthralgia, nausea/vomiting, and headache.
| Percentage of Participants | Main Part: TAK-019 |
|---|---|
| Main Part: Percentage of Participants With Solicited Systemic AEs for 7 Days Following the First Single Booster Vaccination | 48.0 |
Unsolicited AEs defines as other AEs than solicited local AEs and solicited systemic AEs.
| Percentage of Participants | Main Part: TAK-019 |
|---|---|
| Main Part: Percentage of Participants With Unsolicited AEs for 28 Days Following the First Single Booster Vaccination | 4.67 |
An SAE was defined as any untoward medical occurrence that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event. Solicited SAEs and unsolicited SAEs were reported.
| Percentage of Participants | Main Part: TAK-019 |
|---|---|
| Solicited SAEs up to Day 29 | 0 |
| Unsolicited SAEs up to Day 29 | 0 |
An AESI was defined as AEs that will be specifically highlighted to the Investigator. AESIs for the study included the Potential Immune Mediated Medical Conditions (PIMMC) and AEs specific to COVID-19. PIMMC is categorized as following; neuroinflammatory disorders, musculoskeletal and connective tissue disorders, vasculitides, gastrointestinal disorders, hepatic disorders, renal disorders, cardiac disorders, skin disorder, hematologic disorders, metabolic disorders, and other disorders.
| Percentage of Participants | Main Part: TAK-019 |
|---|---|
| Main Part: Percentage of Participants With Adverse Event of Special Interest (AESI) Until Day 29 | 0 |
MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.
| Percentage of Participants | Main Part: TAK-019 |
|---|---|
| Main Part: Percentage of Participants With Medically-Attended Adverse Events (MAAEs) Until Day 29 | 0.7 |
Percentage of participants with any AE leading to withdrawal from the trial until Day 29 was reported.
| Percentage of Participants | Main Part: TAK-019 |
|---|---|
| Main Part: Percentage of Participants With Any AE Leading to Withdrawal From the Trial Until Day 29 | 0 |
Percentage of participants with SARS-CoV-2 infection until Day 29 of the main part of the trial were reported in this outcome measure.
| Percentage of Participants | Main Part: TAK-019 |
|---|---|
| Main Part: Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Until Day 29 | 0 |
GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ. LLOQ was equal to 200 EU/mL.
| EU/mL | Main Part: TAK-019 |
|---|---|
| At Day 8 | 24705.9 (21894.6 to 27878.2) |
| At Day 15 | 35202.2 (31508.4 to 39329.1) |
| At Day 29 | 36138.3 (32143.8 to 40629.2) |
| At Day 91 | 26420.8 (23137.2 to 30170.4) |
| At Day 181 | 20246.3 (11976.5 to 34226.5) |
| At Day 366 | 31369.4 (15135.7 to 65014.5) |
GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Where baseline was defined as the last measurement taken before the first dose of trial vaccination.
| fold rise | Main Part: TAK-019 |
|---|---|
| At Day 8 | 4.21 (3.69 to 4.81) |
| At Day 15 | 6.00 (5.17 to 6.97) |
| At Day 29 | 6.16 (5.23 to 7.27) |
| At Day 91 | 4.43 (3.67 to 5.36) |
| At Day 181 | 2.96 (1.45 to 6.04) |
| At Day 366 | 4.28 (1.33 to 13.77) |
SCR was defined as percentage of participants with 4-fold or more rises from baseline in titer. Baseline was defined as the last measurement taken before the first dose of trial vaccination.
| percentage of participants | Main Part: TAK-019 |
|---|---|
| At Day 8 | 53.4 (45.0 to 61.6) |
| At Day 15 | 70.9 (62.9 to 78.1) |
| At Day 29 | 70.3 (62.2 to 77.5) |
| At Day 91 | 56.1 (47.5 to 64.5) |
| At Day 181 | 40.0 (16.3 to 67.7) |
| At Day 366 | 61.5 (31.6 to 86.1) |
The neutralization titer was expressed as the reciprocal of the highest dilution at which greater than or equal to (\>=) 50 percent (%) of the replicate wells were protected from infection (microneutralization \[MN\] with an inhibitory concentration of 50% \[MN50\]). GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ where LLOQ was equal to 20.
| 1 per dilution | Main Part: TAK-019 |
|---|---|
| At Day 8 | 729.7 (634.5 to 839.2) |
| At Day 15 | 1143.9 (1000.5 to 1307.9) |
| At Day 29 | 775.5 (693.8 to 866.8) |
| At Day 91 | 656.2 (559.6 to 769.4) |
| At Day 181 | 844.5 (410.0 to 1739.3) |
| At Day 366 | 1424.0 (597.0 to 3396.9) |
The neutralization titer was expressed as the reciprocal of the highest dilution at which \>=50% of the replicate wells were protected from infection (MN50). GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Baseline was defined as the last measurement taken before the first dose of trial vaccination.
| fold rise | Main Part: TAK-019 |
|---|---|
| At Day 8 | 5.32 (4.55 to 6.23) |
| At Day 15 | 8.34 (6.93 to 10.04) |
| At Day 29 | 5.66 (4.68 to 6.84) |
| At Day 91 | 4.72 (3.72 to 5.97) |
| At Day 181 | 5.79 (2.43 to 13.80) |
| At Day 366 | 9.90 (2.84 to 34.54) |
The neutralization titer was expressed as the reciprocal of the highest dilution at which greater than or equal to (\>=) 50% of the replicate wells were protected from infection (MN50). SCR was defined as percentage of participants with 4-fold or more rises in from baseline. Baseline was defined as the last measurement taken before the first dose of trial vaccination.
| percentage of participants | Main Part: TAK-019 |
|---|---|
| At Day 8 | 77.7 (70.1 to 84.1) |
| At Day 15 | 84.5 (77.6 to 89.9) |
| At Day 29 | 75.7 (67.9 to 82.3) |
| At Day 91 | 67.6 (59.2 to 75.3) |
| At Day 181 | 66.7 (38.4 to 88.2) |
| At Day 366 | 76.9 (46.2 to 95.0) |
An SAE was defined as any untoward medical occurrence that: Results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event. Solicited SAEs and unsolicited SAEs were reported.
| percentage of participants | Main Part: TAK-019 |
|---|---|
| Solicited SAEs Throughout the Main Part of Trial | 0 |
| Unsolicited SAEs Throughout the Main Part of Trial | 0 |
An AESI was defined as AEs that will be specifically highlighted to the Investigator. AESIs for the study included the PIMMC and AEs specific to COVID-19. PIMMC is categorized as following; neuroinflammatory disorders, musculoskeletal and connective tissue disorders, vasculitides, gastrointestinal disorders, hepatic disorders, renal disorders, cardiac disorders, skin disorder, hematologic disorders, metabolic disorders, and other disorders.
| percentage of participants | Main Part: TAK-019 |
|---|---|
| Main Part: Percentage of Participants With AESI Throughout the Main Part of Trial | 0 |
MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.
| percentage of participants | Main Part: TAK-019 |
|---|---|
| Main Part: Percentage of Participants With MAAEs Throughout the Main Part of Trial | 20.0 |
Percentage of participants with any AE leading to participant's withdrawal from the trial from the day of the first single booster vaccination throughout the main part of trial was reported.
| percentage of participants | Main Part: TAK-019 |
|---|---|
| Main Part: Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial From the Day of the First Single Booster Vaccination Throughout the Main Part of Trial | 0 |
Percentage of participants with SARS-CoV-2 infection throughout the main part of trial was reported.
| percentage of participants | Main Part: TAK-019 |
|---|---|
| Main Part: Percentage of Participants With SARS-CoV-2 Infection Throughout the Main Part of Trial | 14.0 |
GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ. LLOQ was equal to 200 EU/mL.
| EU/mL | Extension Part: TAK-019 |
|---|---|
| At Day 15 | 105057.6 (91624.1 to 120460.6) |
| At Day 29 | 88154.1 (77487.0 to 100289.7) |
| At Day 91 | 61090.0 (52488.3 to 71101.2) |
| At Day 181 | 46199.1 (38752.6 to 55076.6) |
| At Day 366 | 62823.7 (51897.3 to 76050.6) |
The GMFR was calculated as the ratio of the post-second-booster-vaccination titer level to extension part baseline titer level. Where extension part baseline was defined as last measurement taken before the second booster vaccination.
| fold rise | Extension Part: TAK-019 |
|---|---|
| At Day 15 | 3.99 (3.47 to 4.59) |
| At Day 29 | 3.32 (2.91 to 3.78) |
| At Day 91 | 2.30 (1.96 to 2.70) |
| At Day 181 | 1.72 (1.43 to 2.08) |
| At Day 366 | 2.33 (1.84 to 2.95) |
SCR was defined as percentage of participants with 4-fold or more rises in titer from extension part baseline. Where extension part baseline was defined as last measurement taken before the second booster vaccination.
| percentage of participants | Extension Part: TAK-019 |
|---|---|
| At Day 15 | 51.4 (41.7 to 61.0) |
| At Day 29 | 40.9 (31.6 to 50.7) |
| At Day 91 | 19.6 (12.6 to 28.4) |
| At Day 181 | 16.7 (10.0 to 25.3) |
| At Day 366 | 28.9 (19.8 to 39.4) |
The neutralization titer was expressed as the reciprocal of the highest dilution at \>= 50% of the replicate wells were protected from infection (MN50). GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ where LLOQ was equal to 20.
| 1 per dilution | Extension Part: TAK-019 |
|---|---|
| At Day 15 | 1716.6 (1463.2 to 2013.9) |
| At Day 29 | 1732.1 (1465.8 to 2046.8) |
| At Day 91 | 1255.4 (1019.2 to 1546.3) |
| At Day 181 | 1360.7 (1081.2 to 1712.6) |
| At Day 366 | 660.0 (531.0 to 820.4) |
The neutralization titer was expressed as the reciprocal of the highest dilution at \>= 50% of the replicate wells were protected from infection (MN50). The GMFR was calculated as the ratio of the post-second-booster-vaccination titer level to extension part baseline titer level. Where extension part baseline was defined as last measurement taken before the second booster vaccination.
| fold rise | Extension Part: TAK-019 |
|---|---|
| At Day 15 | 3.04 (2.59 to 3.57) |
| At Day 29 | 3.05 (2.57 to 3.63) |
| At Day 91 | 2.19 (1.81 to 2.66) |
| At Day 181 | 2.34 (1.86 to 2.94) |
| At Day 366 | 1.16 (0.86 to 1.55) |
The neutralization titer was expressed as the reciprocal of the highest dilution at \>= 50% of the replicate wells were protected from infection (MN50). SCR was defined as percentage of participants with 4-fold or more rises in titer from extension part baseline.
| percentage of participants | Extension Part: TAK-019 |
|---|---|
| At Day 15 | 51.4 (41.7 to 61.0) |
| At Day 29 | 52.7 (43.0 to 62.3) |
| At Day 91 | 30.8 (22.3 to 40.5) |
| At Day 181 | 36.3 (27.0 to 46.4) |
| At Day 366 | 24.4 (16.0 to 34.6) |
AE was defined as any untoward medical occurrence in a clinical investigation participant administered an investigational medicinal product (IMP); it did not necessarily have to have a causal relationship with IMP administration. Reported solicited local AEs were defined as injection site pain, tenderness, erythema/redness, induration, and swelling.
| percentage of participants | Extension Part: TAK-019 |
|---|---|
| Extension Part: Percentage of Participants With Reported Solicited Local AEs for 7 Days Following the Second Single Booster Vaccination in Extension Part | 73.6 |
Solicited systemic AEs included were defined as fever, fatigue, malaise, myalgia, arthralgia, nausea/vomiting and headache.
| percentage of participants | Extension Part: TAK-019 |
|---|---|
| Extension Part: Percentage of Participants With Solicited Systemic AEs for 7 Days Following the Second Single Booster Vaccination in Extension Part | 51.2 |
Unsolicited AEs defined as AEs other than solicited local AEs and solicited systemic AEs.
| percentage of participants | Extension Part: TAK-019 |
|---|---|
| Extension Part: Percentage of Participants With Unsolicited AEs for 28 Days Following the Second Single Booster Vaccination in Extension Part | 7.0 |
An SAE was defined as any untoward medical occurrence that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event. Solicited SAEs and unsolicited SAEs were reported.
| percentage of participants | Extension Part: TAK-019 |
|---|---|
| Solicited SAEs Up to Extension Part Day 29 | 0 |
| Unsolicited SAEs Up to Extension Part Day 29 | 0.8 |
An AESI was defined as AEs that will be specifically highlighted to the investigator. AESIs for the study included the PIMMC and AEs specific to COVID-19. PIMMC is categorized as following; neuroinflammatory disorders, musculoskeletal and connective tissue disorders, vasculitides, gastrointestinal disorders, hepatic disorders, renal disorders, cardiac disorders, skin disorder, hematologic disorders, metabolic disorders, and other disorders.
| percentage of participants | Extension Part: TAK-019 |
|---|---|
| Extension Part: Percentage of Participants With AESIs Until Extension Part Day 29 | 0 |
MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.
| percentage of participants | Extension Part: TAK-019 |
|---|---|
| Extension Part: Percentage of Participants With MAAEs Until Extension Part Day 29 | 5.4 |
Percentage of participants with any AEs leading to withdrawal from the trial until extension part Day 29 was reported.
| percentage of participants | Extension Part: TAK-019 |
|---|---|
| Extension Part: Percentage of Participants With Any AEs Leading to Withdrawal From the Trial Until Extension Part Day 29 | 0 |
Percentage of participants with SARS-CoV-2 infection until extension part Day 29 was reported.
| percentage of participants | Extension Part: TAK-019 |
|---|---|
| Extension Part: Percentage of Participants With SARS-CoV-2 Infection Until Extension Part Day 29 | 0 |
An SAE was defined as any untoward medical occurrence that: Results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Leads to a congenital anomaly/birth defect in the offspring of a participant, or Is an important medical event. Solicited SAEs and unsolicited SAEs were reported.
| percentage of participants | Extension Part: TAK-019 |
|---|---|
| Solicited SAEs Throughout the Extension Part | 0 |
| Unsolicited SAEs Throughout the Extension Part | 3.1 |
An AESI was defined as AEs that will be specifically highlighted to the Investigator. AESIs for the study included the PIMMC and AEs specific to COVID-19. PIMMC is categorized as following; neuroinflammatory disorders, musculoskeletal and connective tissue disorders, vasculitides, gastrointestinal disorders, hepatic disorders, renal disorders, cardiac disorders, skin disorder, hematologic disorders, metabolic disorders, and other disorders.
| percentage of participants | Extension Part: TAK-019 |
|---|---|
| Extension Part: Percentage of Participants With AESIs Throughout the Extension Part of the Trial | 0 |
MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.
| percentage of participants | Extension Part: TAK-019 |
|---|---|
| Extension Part: Percentage of Participants With MAAEs Throughout the Extension Part of the Trial | 31.0 |
Percentage of participants with any AEs leading to withdrawal from the trial from the day of the second single booster vaccination throughout the extension part of the trial was reported.
| percentage of participants | Extension Part: TAK-019 |
|---|---|
| Extension Part: Percentage of Participants With Any AEs Leading to Withdrawal From the Trial From the Day of the Second Single Booster Vaccination Throughout the Extension Part of the Trial | 0 |
Percentage of participants with SARS-CoV-2 infection throughout the extension part of trial was reported.
| percentage of participants | Extension Part: TAK-019 |
|---|---|
| Extension Part: Percentage of Participants With SARS-CoV-2 Infection Throughout the Extension Part of Trial | 10.9 |
Collected over Main Part: Day 1 up to 366 and Extension Part: Day 1 up to Day 366 (Participants who participated in the Main Part and the Extension Part, total participation duration was approximately 17 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Main Part: TAK-019 | 0/150 (0%) | 0/150 (0%) | 123/150 (82%) |
| Extension Part: TAK-019 | 0/129 (0%) | 4/129 (3.1%) | 107/129 (82.9%) |
| Event | Main Part: TAK-019 | Extension Part: TAK-019 |
|---|---|---|
| Cerebral thrombosisNervous system disorders | 0/150 | 1/129 |
| IleusGastrointestinal disorders | 0/150 | 1/129 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/150 | 1/129 |
| Spinal compression fractureInjury, poisoning and procedural complications | 0/150 | 1/129 |
| Event | Main Part: TAK-019 | Extension Part: TAK-019 |
|---|---|---|
| TendernessGeneral disorders | 102/150 | 89/129 |
| Injection site painGeneral disorders | 80/150 | 65/129 |
| MalaiseGeneral disorders | 39/150 | 44/129 |
| HeadacheNervous system disorders | 37/150 | 37/129 |
| MyalgiaMusculoskeletal and connective tissue disorders | 29/150 | 34/129 |
| FatigueGeneral disorders | 28/150 | 33/129 |
| COVID-19Infections and infestations | 21/150 | 14/129 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 11/150 | 18/129 |
| NauseaGastrointestinal disorders | 10/150 | 11/129 |
| SwellingGeneral disorders | 7/150 | 11/129 |
Main Part: The safety analysis set included all participants who received at least 1 dose of the trial vaccination.
| Age, Continuous(Years) | Main Part: TAK-019 |
|---|---|
| Mean | 45.7 ± 13.00 |
| Sex: Female, Male(Participants) | Main Part: TAK-019 |
|---|---|
| Female | 78 |
| Male | 72 |
| Race (NIH/OMB)(Participants) | Main Part: TAK-019 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 150 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Main Part: TAK-019 |
|---|---|
| Japan | 150 |
| Weight(Kilograms (kg)) | Main Part: TAK-019 |
|---|---|
| Mean | 61.70 ± 11.497 |
| Height(Centimeter (cm)) | Main Part: TAK-019 |
|---|---|
| Mean | 164.47 ± 9.408 |
| BMI(Kilogram (kg)/meter (m)^2) | Main Part: TAK-019 |
|---|---|
| Mean | 22.68 ± 2.940 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Apr 2022 to primary completion in Jun 2022, 1 month.
Results were first posted in Jul 2023, 1 year 1 month after primary completion.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 1 month is below that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NVX-CoV2373 adjuvated lipid nanoparticle